# Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention

Study · id `cardio:ct-nct06909565` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06909565](<https://clinicaltrials.gov/study/NCT06909565>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT06909565

Browse, organ or system: Heart; Metabolism  
Browse, condition area: Risk and prevention; Coronary and vascular disease; Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 6000 participants.

## Technical summary

Registry record NCT06909565. Randomized; quadruple masking; primary purpose prevention. Start 2025-07-23 (actual); primary completion 2029-10 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 6000 participants (planned count; ClinicalTrials.gov record NCT06909565, source copy `cardio:ctgov-nct06909565-2026-11-16`, retrieved 2026-11-18)
- Started: 2025-07-23 (actual) (ClinicalTrials.gov record NCT06909565, source copy `cardio:ctgov-nct06909565-2026-11-16`, retrieved 2026-11-18)
- Primary completion: 2029-10 (anticipated) (ClinicalTrials.gov record NCT06909565, source copy `cardio:ctgov-nct06909565-2026-11-16`, retrieved 2026-11-18)
- Completion: 2029-12 (anticipated) (ClinicalTrials.gov record NCT06909565, source copy `cardio:ctgov-nct06909565-2026-11-16`, retrieved 2026-11-18)
- Countries: United States (ClinicalTrials.gov record NCT06909565, source copy `cardio:ctgov-nct06909565-2026-11-16`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06909565-2026-11-16`, retrieved 2026-11-18)

## The registry's words

- Brief title: Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention
- Acronym: V-INTERVENTION
- Condition: Percutaneous Coronary Intervention
- Condition: Peripheral Endovascular Intervention
- Intervention (Drug): Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
- Intervention (Drug): Normal Saline (Placebo)
- Lead sponsor: Duke University
- Lead sponsor class: OTHER
- Collaborator: Novartis Pharmaceuticals
- Collaborator class: INDUSTRY
- Collaborator: Colorado Prevention Center
- Collaborator class: OTHER
- Collaborator: Mount Sinai Hospital, New York
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry lists this organization as the lead sponsor: Duke University (`cardio:org-duke-university`)
- Registry lists this organization as a collaborator: Novartis (`cardio:novartis`)
- Registry lists this organization as a collaborator: Colorado Prevention Center (`cardio:org-colorado-prevention-center`)
- Registry lists this organization as a collaborator: Mount Sinai Hospital, New York (`cardio:org-mount-sinai-hospital-new-york`)

## Provenance

Content hash: ddfcb49ff8dc8d2c8cf0035d7e157ba93917a91078e76e1b15811bafffa4da60
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
